Is EDIT or ESLA more undervalued in 2026?

CirclFi compares Editas Medicine, Inc. (EDIT) and Estrella Immunopharma, Inc. (ESLA) using 13 institutional-grade valuation models. EDIT has a Quality of Company score of 6.5/10 while ESLA scores 3.1/10.

Which is a better buy — EDIT or ESLA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do EDIT and ESLA valuations compare?

EDIT at $3.46 and ESLA at $1.09 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

EDIT vs ESLA Valuation Comparison 2026 — Intrinsic Value Analysis

EDIT

Biological Products, (No Diagnostic Substances)

Editas Medicine, Inc.

Quality

6.5

out of 10

Value Trap

SAFE

Price

$3.46

Last close

Models

9/13

Active

ESLA

Biological Products, (No Diagnostic Substances)

Estrella Immunopharma, Inc.

Quality

3.1

out of 10

Value Trap

SAFE

Price

$1.09

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	EDIT Fair Value	EDIT Upside	ESLA Fair Value	ESLA Upside
Bayesian DCF	Intrinsic	$1.06	-69.4%	$0.32	-70.3%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$2.00	-42.1%	—	—
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	—	—	$1.51	+35.0%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for EDIT vs ESLA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

EDIT vs ESLA — Which Stock Is More Undervalued?

EDIT scores higher with a 6.5/10 quality rating vs ESLA's 3.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Editas Medicine, Inc. (EDIT) and Estrella Immunopharma, Inc. (ESLA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

EDIT currently trades at $3.46 with a QOC of 6.5/10, while ESLA trades at $1.09 with a QOC of 3.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).